Dowling & Yahnke’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $7.13M | Buy |
14,060
+63
| +0.5% | +$35.3K | 0.33% | 75 |
|
|
2022
Q2 | $7.6M | Buy |
13,997
+677
| +5% | +$373K | 0.36% | 73 |
|
|
2022
Q1 | $7.87M | Buy |
13,320
+236
| +2% | +$136K | 0.34% | 84 |
|
|
2021
Q4 | $8.73M | Sell |
13,084
-199
| -1% | -$124K | 0.42% | 75 |
|
|
2021
Q3 | $7.59M | Buy |
13,283
+202
| +2% | +$111K | 0.42% | 75 |
|
|
2021
Q2 | $6.6M | Buy |
13,081
+355
| +3% | +$167K | 0.38% | 79 |
|
|
2021
Q1 | $5.81M | Sell |
12,726
-100
| -0.8% | -$47.7K | 0.4% | 84 |
|
|
2020
Q4 | $5.97M | Sell |
12,826
-240
| -2% | -$113K | 0.43% | 74 |
|
|
2020
Q3 | $5.77M | Sell |
13,066
-486
| -4% | -$201K | 0.46% | 68 |
|
|
2020
Q2 | $4.91M | Sell |
13,552
-226
| -2% | -$75.8K | 0.41% | 72 |
|
|
2020
Q1 | $3.91M | Sell |
13,778
-228
| -2% | -$71.9K | 0.38% | 74 |
|
|
2019
Q4 | $4.55M | Buy |
14,006
+440
| +3% | +$133K | 0.35% | 87 |
|
|
2019
Q3 | $3.95M | Buy |
13,566
+342
| +3% | +$97.9K | 0.33% | 95 |
|
|
2019
Q2 | $3.88M | Buy |
13,224
+852
| +7% | +$235K | 0.32% | 90 |
|
|
2019
Q1 | $3.39M | Buy |
12,372
+324
| +3% | +$80.6K | 0.33% | 90 |
|
|
2018
Q4 | $3.01M | Buy |
12,048
+468
| +4% | +$110K | 0.31% | 91 |
|
|
2018
Q3 | $2.83M | Sell |
11,580
-36
| -0.3% | -$8.28K | 0.25% | 111 |
|
|
2018
Q2 | $2.41M | Sell |
11,616
-64
| -0.5% | -$13.6K | 0.22% | 123 |
|
|
2018
Q1 | $2.41M | Buy |
11,680
+440
| +4% | +$92.4K | 0.23% | 123 |
|
|
2017
Q4 | $2.13M | Buy |
11,240
+314
| +3% | +$60.2K | 0.19% | 137 |
|
|
2017
Q3 | $2.07M | Buy |
10,926
+251
| +2% | +$45.5K | 0.21% | 133 |
|
|
2017
Q2 | $1.86M | Buy |
10,675
+301
| +3% | +$50.6K | 0.2% | 135 |
|
|
2017
Q1 | $1.59M | Buy |
10,374
+471
| +5% | +$72K | 0.17% | 148 |
|
|
2016
Q4 | $1.4M | Buy |
9,903
+565
| +6% | +$83.3K | 0.16% | 152 |
|
|
2016
Q3 | $1.49M | Buy |
9,338
+252
| +3% | +$38.8K | 0.17% | 142 |
|
|
2016
Q2 | $1.34M | Sell |
9,086
-1,290
| -12% | -$190K | 0.16% | 145 |
|
|
2016
Q1 | $1.47M | Buy |
10,376
+3,314
| +47% | +$444K | 0.18% | 135 |
|
|
2015
Q4 | $1M | Sell |
7,062
-12
| -0.2% | -$1.6K | 0.13% | 156 |
|
|
2015
Q3 | $865K | Buy |
7,074
+492
| +7% | +$64.1K | 0.12% | 158 |
|
|
2015
Q2 | $854K | Buy |
6,582
+440
| +7% | +$57.4K | 0.11% | 162 |
|
|
2015
Q1 | $825K | Buy |
6,142
+138
| +2% | +$17.8K | 0.1% | 165 |
|
|
2014
Q4 | $752K | Buy |
6,004
+801
| +15% | +$97.4K | 0.09% | 165 |
|
|
2014
Q3 | $633K | Buy |
5,203
+886
| +21% | +$108K | 0.08% | 172 |
|
|
2014
Q2 | $509K | Sell |
4,317
-1,283
| -23% | -$151K | 0.07% | 189 |
|
|
2014
Q1 | $673K | Buy |
5,600
+315
| +6% | +$37.5K | 0.09% | 169 |
|
|
2013
Q4 | $588K | Buy |
5,285
+2,455
| +87% | +$244K | 0.08% | 178 |
|
|
2013
Q3 | $261K | Buy |
2,830
+160
| +6% | +$14.5K | 0.04% | 211 |
|
|
2013
Q2 | $226K | Buy |
+2,670
| New | +$222K | 0.04% | 215 |
|
Other funds holding TMO
Dowling & Yahnke's TMO Position: Q3 2022 in Review
Dowling & Yahnke increased its Thermo Fisher Scientific (TMO) stake by 0.45% in Q3 2022, buying an estimated $35.3K and bringing the position to 14,060 shares worth $7.13M. The position accounts for 0.33% of the portfolio, ranked #75.
Dowling & Yahnke first reported a position in TMO in Q2 2013 and has held it in 38 quarters since. The position peaked at $8.73M in Q4 2021. 2,267 funds tracked by Wall St. Rank hold TMO as of Q3 2022.
- Dowling & Yahnke held 14,060 shares of Thermo Fisher Scientific worth $7.13M as of Q3 2022.
- Dowling & Yahnke bought 63 Thermo Fisher Scientific shares in Q3 2022, an estimated $35.3K.
- Thermo Fisher Scientific made up 0.33% of Dowling & Yahnke's portfolio in Q3 2022, its #75 holding.
- Dowling & Yahnke first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 38 quarters since.
- Dowling & Yahnke's Thermo Fisher Scientific position peaked at $8.73M in Q4 2021.
- 2,267 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.